SynCore Biotechnology Co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 09, 2021
Share
SynCore Biotechnology Co.,Ltd reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was TWD 1.48 million compared to TWD 3.93 million a year ago. Net loss was TWD 218.65 million compared to TWD 101.99 million a year ago. Basic loss per share from continuing operations was TWD 1.9 compared to TWD 0.96 a year ago.
For the nine months, sales was TWD 4.07 million compared to TWD 7.67 million a year ago. Net loss was TWD 378.46 million compared to TWD 296.26 million a year ago. Basic loss per share from continuing operations was TWD 3.34 compared to TWD 2.87 a year ago.
SynCore Biotechnology Co.,Ltd is a Taiwan-based company principally engaged in the research, development, production and sales of therapeutic drugs. The Company's main product is SB03 Veregen. The Company is also involved in research, development and clinical trials of the injection-type anticancer drug, SB01 and the oral anticancer drug, SB01. The Company distributes its products mainly in domestic market.